Literature DB >> 26784983

Impact of PEG and PEG-b-PAGE modified PLGA on nanoparticle formation, protein loading and release.

René Rietscher1, Justyna A Czaplewska2, Tobias C Majdanski2, Michael Gottschaldt2, Ulrich S Schubert2, Marc Schneider3, Claus-Michael Lehr4.   

Abstract

The effect of modifying the well-established pharmaceutical polymer PLGA by different PEG-containing block-copolymers on the preparation of ovalbumin (OVA) loaded PLGA nanoparticles (NPs) was studied. The used polymers contained poly(d,l-lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG) and poly(allyl glycidyl ether) (PAGE) as building blocks. The double emulsion technique yielded spherical NPs in the size range from 170 to 220 nm (PDI<0.15) for all the differently modified polymers, allowing to directly compare protein loading of and release. PEGylation is usually believed to increase the hydrophilic character of produced particles, favoring encapsulation of hydrophilic substances. However, in this study simple PEGylation of PLGA had only a slight effect on protein release. In contrast, incorporating a PAGE block between the PEG and PLGA units, also eventually enabling active targeting introducing a reactive group, led to a significantly higher loading (+25%) and release rate (+100%), compared to PLGA and PEG-b-PLGA NPs.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug delivery; Ovalbumin; Poly(allyl glycidyl ether); Poly(d,l-lactic-co-glycolic acid); Polyethylene glycol; Protein delivery

Mesh:

Substances:

Year:  2016        PMID: 26784983     DOI: 10.1016/j.ijpharm.2016.01.021

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  PEGylation enables subcutaneously administered nanoparticles to induce antigen-specific immune tolerance.

Authors:  Peter Y Li; Frank Bearoff; Pu Zhu; Zhiyuan Fan; Yucheng Zhu; Mingyue Fan; Laura Cort; Taku Kambayashi; Elizabeth P Blankenhorn; Hao Cheng
Journal:  J Control Release       Date:  2021-01-12       Impact factor: 9.776

2.  Development and Characterization of PLGA Nanoparticles Containing 17-DMAG, an Hsp90 Inhibitor.

Authors:  Kercia P Cruz; Beatriz F C Patricio; Vinícius C Pires; Marina F Amorim; Alan G S F Pinho; Helenita C Quadros; Diana A S Dantas; Marcelo H C Chaves; Fabio R Formiga; Helvécio V A Rocha; Patrícia S T Veras
Journal:  Front Chem       Date:  2021-05-13       Impact factor: 5.221

3.  The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats.

Authors:  Fang Wang; Yu Deng; Jieting Wang; Luying Yu; Fadian Ding; Wei Lian; Qicai Liu; Xinhua Lin
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

4.  Curcumin-coordinated nanoparticles with improved stability for reactive oxygen species-responsive drug delivery in lung cancer therapy.

Authors:  Cheng-Qiong Luo; Lei Xing; Peng-Fei Cui; Jian-Bin Qiao; Yu-Jing He; Bao-An Chen; Liang Jin; Hu-Lin Jiang
Journal:  Int J Nanomedicine       Date:  2017-01-25

5.  Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization.

Authors:  Lucía Martínez-Jothar; Nataliia Beztsinna; Cornelus F van Nostrum; Wim E Hennink; Sabrina Oliveira
Journal:  Mol Pharm       Date:  2019-03-12       Impact factor: 4.939

6.  Encapsulation of the reductase component of p-hydroxyphenylacetate hydroxylase in poly(lactide-co-glycolide) nanoparticles by three different emulsification techniques.

Authors:  Komkrich Sawasdee; Jeerus Sucharitakul; Taweesak Dhammaraj; Nuttawee Niamsiri; Pimchai Chaiyen; Kanlaya Prapainop
Journal:  IET Nanobiotechnol       Date:  2018-06       Impact factor: 1.847

7.  Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function.

Authors:  Jason Thomas Duskey; Federica da Ros; Ilaria Ottonelli; Barbara Zambelli; Maria Angela Vandelli; Giovanni Tosi; Barbara Ruozi
Journal:  Molecules       Date:  2020-10-09       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.